Ekso Bionics Holdings Dirección

Dirección controles de criterios 4/4

El CEO de Ekso Bionics Holdings' es Scott Davis , nombrado en Dec 2022, tiene una permanencia de 1.5 años. compensación anual total es $637.02K, compuesta por 58.9% salario y 41.1% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.57% de las acciones de la empresa, por valor de €96.91K. La antigüedad media del equipo directivo y de la junta directiva es de 2.4 años y 3 años, respectivamente.

Información clave

Scott Davis

Chief Executive Officer (CEO)

US$637.0k

Compensación total

Porcentaje del salario del CEO	58.9%
Permanencia del CEO	1.8yrs
Participación del CEO	0.5%
Permanencia media de la dirección	2.5yrs
Promedio de permanencia en la Junta Directiva	3.3yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Scott Davis en comparación con los beneficios de Ekso Bionics Holdings?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	-US$12m
Mar 31 2024	n/a	n/a	-US$14m
Dec 31 2023	US$637k	US$375k	-US$15m
Sep 30 2023	n/a	n/a	-US$15m
Jun 30 2023	n/a	n/a	-US$16m
Mar 31 2023	n/a	n/a	-US$15m
Dec 31 2022	US$1m	US$370k	-US$15m

Compensación vs. Mercado: La compensación total ($USD637.02K) de Scott está en línea con el promedio de empresas de tamaño similar en el mercado German ($USD496.69K).

Compensación vs. Ingresos: La compensación de Scott ha sido consistente con los resultados de la empresa en el último año.

CEO

Scott Davis (54 yo)

1.8yrs

Permanencia

US$637,020

Compensación

Mr. Scott G. Davis serves as Chief Executive Officer of Ekso Bionics Holdings, Inc. since December 04, 2022 and serves as Director since December 08, 2022, and also served as its President & Chief Operatin...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Scott Davis	CEO & Director	1.8yrs	US$637.02k	0.48% $ 98.5k
Jerome Wong	Chief Financial Officer	2.3yrs	US$726.08k	0.21% $ 42.7k
Jason Jones	Chief Operating Officer	1.8yrs	US$710.24k	0.22% $ 45.9k
Rachael Anderson	Global Director of Marketing & Strategic Growth	3.8yrs	sin datos	sin datos
Ann Cookson	Human Resources Director	2.5yrs	sin datos	sin datos
Foon Chwee	President of APAC	6.8yrs	sin datos	sin datos
Stephan Aderhold	Senior VP & GM of EMEA	2.8yrs	sin datos	sin datos

2.5yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de 23E2 se considera experimentado (2.4 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Scott Davis	CEO & Director	1.8yrs	US$637.02k	0.48% $ 98.5k
Sherri Medina	Member of Advisory Council	no data	sin datos	sin datos
Hans Keirstead	Member of Advisory Council	no data	sin datos	sin datos
Mary Cloyd	Independent Director	3.8yrs	US$147.01k	0.66% $ 134.8k
Corinna Lathan	Lead Independent Director	2.8yrs	US$158.13k	0.69% $ 140.2k
Nancy Byl	Member of Advisory Council	no data	sin datos	sin datos
Tom Kelley	Member of Advisory Council	no data	sin datos	sin datos
Daniel Kraft	Member of Advisory Council	no data	US$72.21k	sin datos
Kel Bergmann	Member of Advisory Council	no data	sin datos	sin datos
Graham Creasey	Member of Advisory Council	no data	sin datos	sin datos
Suzy Kim	Member of Advisory Council	no data	sin datos	sin datos
Charles Li	Independent Director	6.6yrs	US$143.10k	0.37% $ 75.0k

3.3yrs

Permanencia media

55yo

Promedio de edad

Junta con experiencia: La junta directiva de 23E2 se considera experimentada (3 años de antigüedad promedio).

Ekso Bionics Holdings Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

Ekso Bionics Holdings, Inc. Appoints Deborah Lafer Scher to its Board of Directors

Ekso Bionics Holdings, Inc., Annual General Meeting, Jun 06, 2024

Executive Chairman of the Board recently sold €61k worth of stock

High number of new and inexperienced directors

Ekso Bionics Holdings, Inc Announces Director Changes

Ekso Bionics Holdings, Inc. Approves Appointment of Jerome Wong as Corporate Secretary and Principal Financial Officer

Recent updates

New major risk - Shareholder dilution

Ekso Bionics Holdings, Inc. has completed a Composite Units Offering in the amount of $5.9971 million.

Ekso Bionics Holdings, Inc. has completed a Composite Units Offering in the amount of $6 million.

New major risk - Financial position

Forecast to breakeven in 2026

New minor risk - Profitability

Second quarter 2024 earnings released: US$0.13 loss per share (vs US$0.31 loss in 2Q 2023)

Ekso Bionics Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Ekso Bionics Holdings, Inc. to Report Q2, 2024 Results on Jul 29, 2024

Ekso Bionics Holdings, Inc. Appoints Deborah Lafer Scher to its Board of Directors

Forecast to breakeven in 2026

First quarter 2024 earnings released: US$0.20 loss per share (vs US$0.33 loss in 1Q 2023)

Ekso Bionics Holdings, Inc., Annual General Meeting, Jun 06, 2024

Ekso Bionics Holdings, Inc. to Report Q1, 2024 Results on Apr 29, 2024

No longer forecast to breakeven

New minor risk - Profitability

Ekso Bionics Holdings, Inc. to Report Q4, 2023 Results on Mar 04, 2024

Forecast to breakeven in 2026

Ekso Bionics Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $4.6 million.

Ekso Bionics Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $4.6 million.

Ekso Bionics Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $4.6 million.

Ekso Bionics Holdings, Inc. Launches GaitCoach Software for EksoNR

Ekso Bionics Holdings, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023

Ekso Bionics Holdings, Inc. Receives CMS Coding Approval for Ekso Indego Personal

Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.33 loss in 3Q 2022)

Ekso Bionics Holdings, Inc. to Report Q3, 2023 Results on Oct 26, 2023

Ekso Bionics Holdings, Inc. Receives Non-Compliance Notice from Nasdaq

New major risk - Financial position

Second quarter 2023 earnings released: US$0.31 loss per share (vs US$0.23 loss in 2Q 2022)

Ekso Bionics Holdings, Inc. to Report Q2, 2023 Results on Jul 27, 2023

Executive Chairman of the Board recently sold €61k worth of stock

High number of new and inexperienced directors

No longer forecast to breakeven

Full year 2022 earnings released: US$1.16 loss per share (vs US$0.80 loss in FY 2021)

Forecast to breakeven in 2025

Ekso Bionics Holdings, Inc Announces Director Changes

Ekso Bionics Holdings, Inc. acquired Human Motion and Control Business Unit of Parker Hannifin Corporation for $10 million.

Third quarter 2022 earnings released: US$0.33 loss per share (vs US$0.15 loss in 3Q 2021)

Ekso Bionics Holdings, Inc. Approves Appointment of Jerome Wong as Corporate Secretary and Principal Financial Officer

Ekso Bionics Holdings, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Second quarter 2022 earnings released: US$0.23 loss per share (vs US$0.10 loss in 2Q 2021)

Ekso Bionics Holdings, Inc. to Report Q2, 2022 Results on Jul 28, 2022

Ekso Bionics Holdings, Inc. Receives FDA Clearance to Market Its Eksonr(Tm) Robotic Exoskeleton for Use with Multiple Sclerosis Patients

Ekso Bionics Holdings, Inc. Announces Chief Financial Officer Changes

Ekso Bionics Holdings, Inc., Annual General Meeting, Jun 09, 2022

First quarter 2022 earnings released: US$0.36 loss per share (vs US$0.34 loss in 1Q 2021)

Ekso Bionics Holdings, Inc. to Report Q1, 2022 Results on Apr 28, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Ekso Bionics Holdings, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.30 profit in 3Q 2020)

Second quarter 2021 earnings released: US$0.10 loss per share (vs US$1.88 loss in 2Q 2020)

First quarter 2021 earnings released: US$0.34 loss per share (vs US$0.44 loss in 1Q 2020)

Director has left the company

Full year 2020 earnings released: US$2.21 loss per share (vs US$2.53 loss in FY 2019)

Ekso Bionics Holdings, Inc., Annual General Meeting, Jun 10, 2021

Ekso Bionics Holdings, Inc. to Report Q4, 2020 Results on Feb 25, 2021

New 90-day high: €10.50

Ekso Bionics Holdings, Inc. Announces Resignation of Ted Wang as Member of the Board of Director

New 90-day high: €6.40

Ekso Bionics Holdings, Inc. Appoints Charles Li to its Board of Directors

New 90-day high: €6.35

New 90-day high: €5.00

New 90-day low: €3.58

Third-quarter earnings released: Revenue beats expectations

Third quarter earnings released

Ekso Bionics Holdings, Inc. Announces EGM Builders as First Customer to Adopt Evo Technology

New 90-day low: €3.60

Ekso Bionics Holdings, Inc. to Report Q2, 2020 Results on Jul 30, 2020

Ekso Bionics Holdings, Inc.(NasdaqCM:EKSO) dropped from Russell Microcap Growth Index